Supernus Pharmaceuticals

MD - RockvillePharmaceutical1 H-1B visas (FY2023)

Focus: Supernus Pharmaceuticals is a specialty pharmaceutical company focused on neurology with a portfolio of small-molecule therapeutics. The company generates 55% of revenue from its flagship product GOCOVRI, indicating significant concentration risk.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

5 recent layoff filings (12 mo) — 320 affected

2/27/2026 — 117 Waterworks Way Irvine CA 92618, CA · 58 affected · Layoff
2/27/2026 — 1555 Laguna Canyon Road Irvine CA 92618, CA · 176 affected · Layoff
2/27/2026 — 117 Waterworks Way Irvine CA 92618, CA · 58 affected · Layoff
+2 more

Source: state DOL filings via Big Local News

About Supernus Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Supernus Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

2 imminent

OXTELLAR XR

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

GOCOVRI

Parkinson's disease and drug-induced movement disorders

$92M Part D

Peak

Help build intelligence for Supernus Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established commercial operations with proven ability to bring neurology products to market and generate meaningful revenue ($92M Part D spending on GOCOVRI).
Diverse pipeline spanning 30 programs across ADHD, depression, epilepsy, Parkinson's disease, and migraine with multiple Phase 2/3 assets providing near-term catalyst opportunities.
Focused therapeutic strategy in neurology creates depth of expertise and potential for career specialization in a high-need therapeutic area.

Watch Out For

Severe revenue concentration risk with 55% dependency on GOCOVRI, combined with two major patent cliffs approaching ($64M revenue at risk by 2028).
Recent significant workforce reductions (319+ employees across multiple layoffs in 2025-2026) signal financial stress and ongoing restructuring uncertainty.
Zero active job openings listed and minimal current hiring activity suggest limited immediate growth or career advancement opportunities.

Generated by Claude from Supernus Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Flagship revenue driver (55% of total) with long patent exclusivity extending to 2038, though M2 protein inhibitor mechanism limits expansion potential.

TROKENDI XR

Epilepsy, migraine prevention

$33M Part D

LOE Approaching1.8yr

Second-largest revenue source facing patent expiration in 2028; cytochrome P450 inducer with established market but generic competition imminent.

OXTELLAR XR

Epilepsy, seizure disorders

$31M Part D

LOE Approaching0.8yr

Extended-release anticonvulsant with sodium channel blocking mechanism; patent cliff in 2027 will expose revenue to generic erosion.

AMANTADINE

Parkinsonism, drug-induced extrapyramidal reactions, influenza A

$6M Part D

Post-LOE

Post-loss-of-exclusivity product with minimal differentiation; NMDA receptor antagonist with established safety profile but limited growth.

QELBREE

ADHD

$4M Part D

Peak8.8yr

Emerging ADHD therapy with long patent protection (2035) but small current footprint; growth will depend on market penetration.

OSMOLEX ER

Parkinsonism, drug-induced extrapyramidal reactions

$2M Part D

Peak11.7yr

Extended-release amantadine formulation with long patent life (2038) but modest revenue; supports company's neurology franchise in movement disorders.

AMANTADINE HYDROCHLORIDE

Parkinsonism, drug-induced extrapyramidal reactions, influenza A

Post-LOE

Generic amantadine formulation with no exclusivity; minimal commercial significance in competitive generic market.

AMANTADINE HYDROCHLORIDE

Parkinsonism, drug-induced extrapyramidal reactions, influenza A

Post-LOE

Duplicate ANDA entry for amantadine; represents generic product with no differentiation or growth potential.

AMANTADINE HYDROCHLORIDE

Parkinsonism, drug-induced extrapyramidal reactions, influenza A

Post-LOE

Third generic amantadine formulation; indicates mature market presence with ongoing generic competition.

Pipeline & Clinical Trials

National Pregnancy Registry for Psychiatric Medications

Pregnant Women

N/A

Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors

Impulsive Aggression

N/A

Clinical Trials (1)

NCT03615703Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors

N/A

ZULRESSO

Postpartum Depression

N/A

Clinical Trials (1)

NCT03924492Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression

N/A

Observational study

Parkinson Disease

N/A

Clinical Trials (1)

NCT07219927Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

N/A

Assessment of Suicidality in Epilepsy - Rating Tools

Epilepsy

N/A

Oxcarbazepine Extended Release

Epilepsy

N/A

Clinical Trials (1)

NCT00918424Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects

N/A

XADAGO

Idiopathic Parkinson Disease

N/A

Clinical Trials (1)

NCT03944785Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

N/A

SAGE-547

Super-Refractory Status Epilepticus

N/A

Clinical Trials (1)

NCT02433314An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus

N/A

SPN-804O

Epilepsies, Partial

Phase 1

Clinical Trials (1)

NCT00918047Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients

Phase 1

SAGE-718

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT03771586A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Phase 1

SPN-810M

Impulsive Aggression Comorbid With ADHD

Phase 1

Clinical Trials (1)

NCT02023606Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M

Phase 1

[14C]-NV-5138

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05384977Mass Balance Study of NV-5138 in Healthy Male Subjects

Phase 1

[14C]-NV-5138

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05152680Mass Balance Study of NV-5138 in Healthy Male Subjects.

Phase 1

Topiramate IR

Epilepsy

Phase 1

Clinical Trials (1)

NCT01114854A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)

Phase 1

SPN-817, Treatment B

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT05102552Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects

Phase 1

BIS-001 ER

Epilepsy, Complex Partial

Phase 1

Clinical Trials (1)

NCT03156439Bioavailability, Safety, and Tolerability of BIS-001 ER

Phase 1

SAGE-718

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT03844906A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

Phase 1

SAGE-718

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT03770780A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Phase 1

SAGE-718

Huntington Disease

Phase 1

Clinical Trials (1)

NCT03787758A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

Phase 1

SAGE-904

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT05049343Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

Phase 1

BIS-001ER

Focal Impaired Awareness Seizures

Phase 1/2

Clinical Trials (1)

NCT03474770BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

Phase 1/2

IR Viloxazine

Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 1/2

Clinical Trials (1)

NCT01107496Evaluation of Immediate-Release Viloxazine in Adults With ADHD

Phase 1/2

TPM XR

Epilepsy

Phase 1/2

Clinical Trials (1)

NCT01284530Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Phase 1/2

SAGE-547

Super-refractory Status Epilepticus

Phase 1/2

Clinical Trials (1)

NCT02052739Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

Phase 1/2

SPN-817

Focal Onset Seizures

Phase 2

Clinical Trials (1)

NCT07141329SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

Phase 2

SAGE-718

Huntington Disease

Phase 2

Clinical Trials (1)

NCT0535882128-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Phase 2

Brexanolone

Tinnitus

Phase 2

Clinical Trials (1)

NCT05645432An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus

Phase 2

SAGE-718

Alzheimer Disease

Phase 2

Clinical Trials (1)

NCT04602624A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Phase 2

SPN-817

Focal Onset Seizures

Phase 2

Clinical Trials (1)

NCT06798896RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

Phase 2

Molindone

Impulsive Aggression Comorbid With ADHD in Children

Phase 2

Clinical Trials (1)

NCT01416064Open-Label, Extension Study to 810P202

Phase 2

Gocovri

Radiation Encephalopathy

Phase 2

Clinical Trials (1)

NCT07125222Use of Gocovri to Improve Disability Due to Radiation Encephalopathy

Phase 2

SPN-810

Impulsive Aggression Comorbid With ADHD

Phase 2

Clinical Trials (1)

NCT01364662A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

SAGE-718

Parkinson Disease

Phase 2

Clinical Trials (1)

NCT04476017A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

Phase 2

SAGE-547

Postpartum Depression

Phase 2

Clinical Trials (1)

NCT02285504Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

Phase 2

SAGE-718

Huntington's Disease

Phase 2

Clinical Trials (1)

NCT05107128A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Phase 2

Placebo

Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

Clinical Trials (1)

NCT02633527Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

Phase 2

SAGE-718-matching placebo

Parkinson Disease

Phase 2

Clinical Trials (1)

NCT05318937A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Phase 2

SPN-817

Epilepsy

Phase 2

Clinical Trials (1)

NCT05518578Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Phase 2

SAGE-547

Severe Postpartum Depression

Phase 2

Clinical Trials (1)

NCT02614547A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

Phase 2

SPN-810

Attention Deficit Disorder With Hyperactivity

Phase 2

Clinical Trials (1)

NCT00626236Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

Phase 2

NV-5138

Major Depressive Disorder

Phase 2

Clinical Trials (1)

NCT06235905Open-Label of SPN-820 in Adults With Major Depressive Disorder

Phase 2

IR-TPM

Migraine

Phase 2

Clinical Trials (1)

NCT03280342Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine

Phase 2

SPN-821 2400 mg

Major Depressive Disorder (MDD)

Phase 2

Clinical Trials (1)

NCT07226661Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

Phase 2

Functional Magnetic Resonance Imaging

Attention Deficit Hyperactivity Disorder (ADHD)

Phase 2

Clinical Trials (1)

NCT03638466Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

Phase 2

SAGE-718

Mild Cognitive Impairment

Phase 2

Clinical Trials (1)

NCT05619692A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Phase 2

NV-5138

Treatment Resistant Depression

Phase 2

Clinical Trials (1)

NCT05066672Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

Phase 2

Phase 2; Low Dose MYOBLOC

Spasticity

Phase 2/3

Clinical Trials (1)

NCT04099667Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

Phase 2/3

Phase 2; Low Dose MYOBLOC

Spasticity

Phase 2/3

Clinical Trials (1)

NCT04815967Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

Phase 2/3

Placebo

Postpartum Depression

Phase 3

Clinical Trials (1)

NCT02942017A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

Phase 3

SAGE-718

Huntington's Disease

Phase 3

Clinical Trials (1)

NCT05655520A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 9 approved products, 74 clinical trials

Top TAs: Neurology, Infectious Diseases, Psychiatry

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Peak3 (33%)

LOE Approaching2 (22%)

Post-LOE4 (44%)

9 total products

Therapeutic Area Focus

Neurology

8 marketed33 pipeline

5 marketed

4 marketed

4 marketed

2 marketed

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (7)

2026-02-27

58 employees affected— Irvine, CA

2026-02-27

176 employees affected— Irvine, CA

2026-02-27

58 employees affected— Irvine, CA

2025-06-30

27 employees affected— CA

Cardiovascular

1 marketed

1 employees affected— Mojave, CA

2025-06-30

20 employees affected— CA

2025-06-30

5 employees affected— Irvine, CA

Source: state DOL filings, aggregated via Big Local News

Supernus executed significant workforce reductions in June 2025 (53 employees) and February 2026 (292 employees) across California locations, indicating financial pressure and ongoing restructuring.

Multiple recent and ongoing layoffs signal financial stress, patent cliff concerns, and high organizational instability; career security is materially compromised.

Supernus Pharmaceuticals

About Supernus Pharmaceuticals

Why Work Here

Key Products

Watch Out For

Products & Portfolio (4)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (0)

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (7)